Beyond Air Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $7.7M+107.3% YoYTTM through 31 Mar 2026
Net Income -$33.2MTTM through 31 Mar 2026
Free Cash Flow -$19.2MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | -45.6% |
| EBITDA Margin | -337.9% |
| Operating Margin | -1,200.0% |
| Net Margin | -433.0% |
Returns
-325.1%ROE
-155.1%ROA
Balance Sheet Health
Debt / Equity0.68x
Current Ratio3.20x
Net Debt$2.9M
Cash & Equivalents$6.7M
Quality Metrics
Altman Z-Score-14.45
Piotroski F-Score5 / 9
FCF Margin-249.6%
Rule of 40-230.6
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2026: $7.7M
Diluted EPS-$4.01TTMFY2026: $-4.01
Dividend
No dividend
Capital Allocation
Capex Intensity13.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Beyond Air | $3.7M | View detailsFocusing on commercial execution of LungFit PH in the U.S. and international markets, with FDA clearance of the second-generation LungFit PH system anticipated by late calendar 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.